Covid vaccine in skin patches covered with tiny needles made by a British company


Emergex, an Oxfordshire-based company, has created the patch. The patch is more durable than regular Covid vaccinations. Clinical trials will begin soon.

As the British invention enters clinical trials, a Covid-19 vaccine could be administered via a patch of skin covered with tiny needles.

Emergex, a company based in Oxfordshire, has created the patch. They claim it is more effective than regular Covid vaccinations.

The company hopes their patch will trigger an immune response that kills T cells. This could help stop the virus spreading.

Thomas Rademacher is the chief executive officer at Emergex and an emeritus professor in molecular medicine at UCL. He stated: “Our T-cell priming vaccine for Covid was designed to stimulate a T-cell response to kill virally infected cells, before they become factories for this virus.”

“The preclinical data we have suggests that our vaccine will elicit a strong T cell response similar to the longer lasting immune response that is found after many natural viral infections.

“Our vaccine is designed to produce an immune response against high-conserved internal parts of virus. This could potentially protect us against new and existing variants, as well as against related strains of coronaviruses (e.g. SARS-1).

Emergex vaccine has an antigen that can only be found on the surfaces of infected cells.

This activates the immune system and triggers a T cell to search for this protein on the surface of cells. When it finds it, it hits the “kill switch” and kills it.

The vaccine has entered stage one clinical trials. It will be administered to 26 patients in Lausanne (Switzerland).

It could be made available in 2025 if it is successful.

Covid vaccines are also being developed by other companies that can be administered through skin patches.

Australian researchers are also testing a version that contains 5,000 microneedles.